Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Sequencing Challenges Persist in Metastatic Prostate Cancer

July 5th 2018

Scott Samuelson, MD, discusses frontline treatment of patients with prostate cancer and subsequent sequencing.

Dr. Maughan on Enzalutamide Plus Radium-223 in mCRPC

July 4th 2018

Benjamin Maughan, MD, PharmD, instructor, Division of Medical Oncology, Huntsman Cancer Institute, discusses enzalutamide (Xtandi) plus radium-223 (Xofigo) in metastatic castration-resistant prostate cancer.

Study Could Resolve Abiraterone/Docetaxel Debate in Hormone-Sensitive Prostate Cancer

July 2nd 2018

Andy Hahn, MD, discusses the ongoing debate between abiraterone and docetaxel and the optimal patient selection for each agent in patients with metastatic hormone-sensitive prostate cancer.

MRI Combination Techniques Hone Accuracy of Prostate Cancer Diagnosis

July 2nd 2018

Several studies presented at this year’s American Urological Association meeting underscored the value of multiparametric magnetic resonance imaging in the diagnosis and management of prostate cancer.

Dr. Hahn Discusses Abiraterone Versus Docetaxel in Prostate Cancer

June 27th 2018

Andy Hahn, MD, resident, University of Utah School of Medicine, discusses abiraterone acetate (Zytiga) versus docetaxel in the treatment of patients with prostate cancer.

Dr. Yu on Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer

June 25th 2018

Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses treatment intensification in patients with metastatic castration-sensitive prostate cancer.

Study Explores ADT Alternative in Localized Prostate Cancer Recurrence

June 18th 2018

Cryoablation may help men whose prostate cancer recurs after radiation therapy avoid or delay retreatment with androgen deprivation therapy.

Dr. Giri on Genes that Carry a Risk for Prostate Cancer

June 16th 2018

Veda Giri, MD, associate professor, Thomas Jefferson University Hospital, discusses genes that are associated with a risk of developing prostate cancer.

Patients Aged

June 13th 2018

Patients younger than 65 years experienced net cancer costs that were higher for breast, colorectal, lung, and prostate cancer compared with patients who were 65 years and older.

Dr. Samuelson on Frontline Treatment and Subsequent Sequencing in Prostate Cancer

June 12th 2018

Scott Samuelson, MD, medical oncologist, Utah Cancer Specialists, on frontline treatment of patients with prostate cancer and subsequent sequencing.

DNA Repair Defects Are Strong Targets for Therapeutic Development in Prostate Cancer

June 11th 2018

The use of PARP inhibitors in patients with a variety of tumor types is backed by a growing body of research, and there is now strong justification for clinical trials of these agents in patients with prostate cancer.

Moving Radium-223 Forward in the Treatment Timeline for Prostate Cancer With Bone Metastases

June 10th 2018

Moving radium-223 (Xofigo) up in the treatment paradigm for patients with prostate cancer could provide better outcomes and longer survival, according to Richard G. Stock, MD.

A Call for Clinical Research

June 9th 2018

Raoul S. Concepcion, MD, FACS, discusses the importance of research opportunities for residents.

Dr. Halabi Discusses Overall Survival Between African-American and Caucasian Men With mCRPC

June 8th 2018

Susan Halabi, PhD, professor of biostatistics and bioinformatics, School of Medicine, Duke Cancer Institute, discusses overall survival between African-American and Caucasian men with metastatic castration-resistant prostate cancer.

Dr. Maughan Discusses Abiraterone Plus Olaparib in mCRPC

June 7th 2018

Benjamin Maughan, MD, PharmD, instructor, Division of Medical Oncology, Huntsman Cancer Institute, discusses the combination of abiraterone acetate (Zytiga) and olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer.

Dr. Yu on Comorbidities and Therapy Choice in Prostate Cancer

June 6th 2018

Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses how comorbidities factor into treatment choice for patients with castration-sensitive prostate cancer.

Olaparib/Abiraterone Improves PFS in mCRPC

June 6th 2018

Combining olaparib (Lynparza) with abiraterone acetate (Zytiga) reduced the risk of disease progression or death by 35% compared with abiraterone alone in pretreated patients with metastatic castration-resistant prostate cancer.

Dr. Hussain Discusses Findings With PARP Inhibitors in Prostate Cancer

June 5th 2018

Maha Hussain, MD, FACP, FASCO, Genevieve Teuton Professor of Medicine, Deputy Director, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, discusses findings with PARP inhibitors in prostate cancer.

Dr. George on Results of Abi Race Trial in Prostate Cancer

June 2nd 2018

Daniel J. George, MD, professor of medicine, surgery, member, Duke Cancer Institute, discusses the results of the prospective multicenter Abi Race trial, which compared outcomes of African-American and Caucasian patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (Zytiga) and prednisone.

Black Men May Fare Better Than White Men With Standard mCRPC Therapy

June 2nd 2018

Black men with metastatic castration-resistant prostate cancer may experience greater benefits from chemotherapy and hormone-targeting treatment than their white counterparts.